rytmonorm
viatris limited - propafenone hydrochloride 150mg; ; ; propafenone hydrochloride 150mg - tablet - 150 mg - active: propafenone hydrochloride 150mg excipient: croscarmellose sodium hypromellose macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide active: propafenone hydrochloride 150mg excipient: croscarmellose sodium hypromellose macrogol 400 macrogol 6000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified water titanium dioxide - for the treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wolff-parkinson-white (wpw) syndrome. also for the treatment of life-threatening documented ventricular tachyarrhythmia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.
rytmonorm 150mg film-coated tablets
mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - propafenone hydrochloride - film-coated tablet - propafenone hydrochloride 150 mg - cardiac therapy
rytmonorm 150 mg film-coat. tabl.
teva b.v. - propafenone hydrochloride 150 mg - film-coated tablet - 150 mg - propafenone hydrochloride 150 mg - propafenone
rytmonorm 150 mg
abbott medical laboratories ltd, israel - propafenone hydrochloride - film coated tablets - propafenone hydrochloride 150 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.
rytmonorm tablet 150 mg
abbott laboratories (singapore ) private limited - propafenone hcl - tablet, film coated - 150 mg - propafenone hcl 150 mg
rytmonorm
viatris limited - propafenone hydrochloride 300mg - tablet - 300 mg - active: propafenone hydrochloride 300mg excipient: croscarmellose sodium hypromellose macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - for the prophylaxis and treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wpw syndrome. also for the prophylaxis and treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.
rytmonorm 300 mg
abbott medical laboratories ltd, israel - propafenone hydrochloride - film coated tablets - propafenone hydrochloride 300 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.
aropax
glaxosmithkline nz limited - paroxetine hydrochloride 22.8mg equivalent to 20 mg paroxetine; - film coated tablet - 20 mg - active: paroxetine hydrochloride 22.8mg equivalent to 20 mg paroxetine excipient: calcium hydrogen phosphate dihydrate magnesium stearate opadry white ys-1-7003 sodium starch glycolate - aropax is indicated for the treatment of major depressive disorder (mdd). aropax is indicated for the prevention of relapse and also recurrence of further depressive episodes.
rytmonorm tablet 150mg
abbott laboratories (m) sdn. bhd. - propafenone hydrochloride -
rytmonorm 300 mg film-coat. tabl.
teva b.v. - propafenone hydrochloride 300 mg - film-coated tablet - 300 mg - propafenone hydrochloride 300 mg - propafenone